ACOGF News and Press, Alpha Cognition Inc From 06/07/23

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the that it has been awarded a $750,000 grant f...

Not for distribution in the U.S. or to U.S. newswire services. Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the l...

2023-05-30 09:55:15 ET Alpha Cognition ( OTCQB:ACOGF ) has announced a private placement offering of up to $6.5M of units at a price of $0.22/unit. Each unit will consist of one common share and one-half of a share purchase warrant. Each whole warrant will entitle the hold...

Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”) announces a private placement offering of up to $6,500,000 of units at a price of $0.22 per unit. Each unit will consist of one common share and one-half of a share purchase warrant. ...

--News Direct-- Alpha Cognition CEO Michael McFadden joins Natalie Stoberman from the Proactive studio to discuss the company's latest financial growth from new funding and reduced expenses and how its been highlighted by a new listing on the Canadian Stock Exchange. Alpha Cognition i...

Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE. Listing and disclosure documents will be available at www.thecse.com on the trading date. Alpha Cognition Inc. is a clinical sta...

VANCOUVER, BC / ACCESSWIRE / April 5, 2023 / Alpha Cognition Inc. (TSX-V:ACOG)(OTCQB:ACOGF), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday,...

Not for distribution in the United States or to U.S. newswire services Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders...

2023-03-09 09:34:17 ET Alpha Cognition press release ( OTCQB:ACOGF ): Q4 GAAP EPS of -$0.05 misses by $0.02 . Cash and cash equivalents at December 31, 2022 were $2.1 million. For further details see: Alpha Cognition GAAP EPS of -$0.05 misses by $0.02

Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today repor...